David L. Porter
Hospital of the University of Pennsylvania · 441 works · 34,493 citations · h-index 62
Top works
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
- Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
- Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
- Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- Chimeric Antigen Receptor Therapy for Cancer
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience